Treatment Updates

Evolving Concepts in Antiretroviral Therapy

Answering the Questions: Practical Management Strategies to Address Cardiovascular Risk in HIV

Questions And Answers

Modules

• Answering the Questions: Practical Management Strategies to Address Cardiovascular Risk in HIV
• Faculty Response to Readers’ Questions: Practical Management Strategies to Address Cardiovascular Risk in HIV (coming soon)

CCO Slideset

• Answering the Questions: Practical Management Strategies for Cardiovascular Risk in HIV

Evolving Insights Into the Optimal Timing of Antiretroviral Therapy

Virtual Presentation

• Evolving Insights Into the Optimal Timing of Antiretroviral Therapy
• Evolving Insights Into the Optimal Timing of Antiretroviral Therapy

Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents

Virtual Presentation

• Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents
• Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents

Case Vignettes

• Clinical Management of a Patient Who Develops Additional Resistance Mutations When Maintained on a Failing Antiretroviral Regimen
• Selecting an Antiretroviral Regimen in a Treatment-Experienced Patient Who has Never Achieved Undetectable Viral Load
• Using Recently Approved Antiretrovirals in the Management of a Highly Treatment–Experienced HIV-Infected Woman

Simple From the Start: The Importance of Treatment Convenience in Antiretroviral Therapy

Modules

• Recent Advances in Simplifying Antiretroviral Therapy
• Clinical Significance of Simplicity and Adherence in Antiretroviral Therapy

Interactive Case Challenges

• Selection of Initial Therapy for a 48-Year-Old HIV/TB-Coinfected Woman With Cardiovascular Disease Risk Factors
• Management of a 38-Year-Old Male on Methadone Maintenance Therapy Who Presents With PCP
• Management of a 38-Year-Old Otherwise Healthy Married Man Recently Diagnosed With HIV Infection

Managing Cardiovascular Risk in HIV-Infected Patients: The Role of Antiretroviral Selection

Modules

• Latest Insights Into Cardiovascular Risk in HIV-Infected Patients
• Antiretroviral Strategies for Minimizing Cardiovascular Risk

Interactive Case Challenges

• Selection of an Initial Regimen for a Patient With a Family History of Cardiovascular Disease
• Management of Dyslipidemia in an HIV-Infected Man With Grave Cardiac Risk

Slideset Module

• Update on Cardiovascular Risk and Antiretroviral Therapy
• Downloadable Slides: Update on Cardiovascular Risk and Antiretroviral Therapy

HIV Entry and Tropism: New Strategies for Effective Antiretroviral Therapy

Modules

• Understanding HIV Entry and Targets for Therapy
• Tracking Tropism: Epidemiology and Clinical Tools
• Recent Clinical Studies of HIV Entry Inhibitors
• Entry Inhibitors in Clinical Practice: Strategies to Achieve Treatment Goals

CCO Slidesets

• Understanding HIV Entry and Targets for Therapy
• Tracking Tropism: Epidemiology and Clinical Tools
• Recent Clinical Studies of HIV Entry Inhibitors
• Entry Inhibitors in Clinical Practice: Strategies to Achieve Treatment Goals

Right From the Start: Optimizing First-Line Antiretroviral Therapy

Modules

• When to Start Antiretroviral Therapy
• Update on Efficacy and Durability of Recommended Regimens for First-Line Therapy
• Safety and Tolerability of Recommended Regimens for First-Line Therapy
• Aiming for Ease: The Importance of Regimen Convenience in Antiretroviral Therapy

CCO Slidesets

• When to Start Antiretroviral Therapy
• Update on Efficacy and Durability of Recommended Regimens for First-Line Therapy
• Update on Safety and Tolerability of Recommended Regimens for First-Line Therapy
• Aiming for Ease: The Importance of Regimen Convenience In Antiretroviral Therapy

New Classes of Antiretrovirals: The Clinical Role of Integrase Inhibitors and Entry Inhibitors

Modules

• New Classes of Antiretrovirals and How They Work
• How, When, and Why to Use Novel Agents
• Clinical Scenarios for the Use of Novel Agents

Animation

• The Role of Integrase in the HIV Life Cycle

The Clinical Impact of Next-Generation NNRTIs: Recent Research and Practical Treatment Strategies

Questions And Answers

Modules

• Faculty Answers Questions on Next-Generation NNRTIs (coming soon)
• The Next Generation of NNRTIs

Virtual Presentations

• The Clinical Need for Next-Generation NNRTIs
• The Clinical Need for Next-Generation NNRTIs
• The Potential Clinical Impact of Next-Generation NNRTIs
• The Potential Clinical Impact of Next-Generation NNRTIs

Metabolic Complications in HIV-Infected Patients

Virtual Presentations

• Metabolic Complications in HIV-Infected Patients

CCO Slideset

• Metabolic Complications in HIV-Infected Patients

Translations of CCO Slideset

• Complications Métaboliques Chez les Patients Infectés par le VIH (French)
• Metabolische Komplikationen bei HIV-infizierten Patienten (German)
• Complicanze Metaboliche in Pazienti Con Infezione da HIV (Italian)

New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors

Virtual Presentation

• New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors
• New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors

Managing Drug-Drug Interactions in the Changing Landscape of HIV

Modules

• Drug-Drug Interactions in the Treatment of HIV

Interactive Tool

• Drug-Drug Interactions Tool: From the CME-certified program Managing Drug-Drug Interactions in the Changing Landscape of HIV

Recent Advances in Managing Neurologic Adverse Effects of Antiretroviral Therapy

Modules

• Recent Advances in Managing Neurologic Adverse Effects of Antiretroviral Therapy

Interactive Case Challenges

• An HIV-Infected Man Who Presents With Sensory Disturbances
• Clinical Management of an HIV-Positive Man Experiencing Dizziness, Vivid Dreams, and Anxiety

CCO Slidesets

• Recent Advances in Managing Neurologic Adverse Effects of Antiretroviral Therapy

New Protease Inhibitors, New Treatment Goals: Attaining Undetectable Viral Load in Antiretroviral-Experienced Patients

Modules

• Constant Evolution: How PIs Have Changed to Meet Changing Needs
• Considerations When Selecting First-Line and Second-Line PI
• The Role of Protease Inhibitors in the Management of Treatment-Experienced Patients

CCO Slidesets

• Constant Evolution: How Protease Inhibitors Have Changed to Meet Changing Needs
• Considerations When Selecting First-Line and Second-Line Protease Inhibitors
• The Role of Protease Inhibitors in the Management of Treatment-Experienced Patients

Redefining the Frontiers of First-Line Antiretroviral Therapy: A Decade of Progress in Effective HAART

Modules

• How Potent and Durable Can First-Line Therapy Be?
• How Convenient Can First-Line Therapy Be?
• How Well Tolerated Can First-Line Therapy Be?
• How May First-Line Therapy Continue to Evolve?

CCO Slidesets

• How Potent and Durable Can First-Line Therapy Be?
• How Convenient Can First-Line Therapy Be?
• How Well Tolerated Can First-Line Therapy Be?
• How May First-Line Therapy Continue to Evolve?

Refining Antiretroviral Regimens: Improving Tolerability and Convenience for Virologically Suppressed HIV-Infected Patients

Virtual Presentations

• 21st Century Therapy: Advances in Antiretroviral Options
• CCO Slideset – 21st Century Therapy: Advances in Antiretroviral Options
• Modifying Antiretroviral Therapy to Improve Convenience in Patients With Virologic Suppression
• CCO Slideset – Modifying Antiretroviral Therapy to Improve Convenience in Patients With Virologic Suppression
• Should We Embrace Proactive Therapy Switches in Patients Who Are Tolerating Their Current Regimen, Based on Concerns About Potential Long-Term Toxicity? Pro and Con Arguments
• CCO Slideset – Debate: Should We Embrace Proactive Therapy Switches in Patients Who Are Tolerating Their Current Regimen, Based on Concerns About Potential Long-term Toxicity?

Understanding HIV Drug Resistance Testing: When to Test, How to Interpret

Virtual Presentations

• Understanding HIV Drug Resistance Testing: When to Test, How to Interpret
• CCO Slideset – Understanding HIV Drug Resistance Testing: When to Test, How to Interpret

A Decade of HAART: Past, Present, and Future Role of Protease Inhibitors

Virtual Presentations

• A Decade of HAART: Past, Present, and Future Roles of Protease Inhibitors
• CCO Slideset – A Decade of HAART: Past, Present, and Future Roles of Protease Inhibitors

On-Demand Teleconference

• A Decade of HAART: Past, Present, and Future Role of Protease Inhibitors

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

On-Demand Video Conference

• Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

CCO Slidesets

• Clinical Data and Development of Agents in Novel Antiretroviral Classes
• How, Where, and When to Use New Agents
• Why Do We Need New Antiretroviral Drugs in Novel Classes and How Do They Work?

Educational Module

• Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

Choosing and Using New Antiretrovirals for Multiclass-Experienced HIV-Infected Patients

Modules

• Research Compendium: Choosing and Using New Antiretrovirals for Multiclass-Experienced HIV-Infected Patients
• CCO Slideset: Choosing and Using New Antiretrovirals for Multiclass-Experienced HIV-Infected Patients

Use of Boosted Protease Inhibitor-Based Regimens in Treatment-Experienced Patients

Modules

• Optimal Use of Boosted PI-Containing Regimens in the Management of Treatment-Experienced Patients

Interactive Case Challenges

• Use of Sequential Boosted-PI Regimens in an HIV-Infected Patient With Adherence Problems
• Balancing Efficacy and Toxicity in a Highly Treatment–Experienced Patient Receiving Boosted PIs
• Management of Adverse Events in an HIV-Infected Woman Receiving Boosted PIs

CCO Slidesets

• Optimal Use of Boosted PIs in Treatment-Experienced Patients

Preventing and Managing Antiretroviral Side Effects

Modules

• Preventing and Managing Antiretroviral Side Effects
• Insulin Resistance and Diabetes
• Fat Atrophy and Accumulation
• Liver Toxicity
• High Lactates and Lactic Acidosis
• Peripheral Neuropathy
• Osteopenia and Osteonecrosis

Antiretroviral Strategies for the Management of HIV Infection

Modules

• When to Start
• What to Start With
• When to Switch
• What to Switch To
• Salvage Strategies
• Structured Treatment Interruption

New Strategies for Regaining Control of HIV Replication in Treatment-Experienced Patients

On-Demand Video Conference

• Webcast: New Strategies for Regaining Control of HIV Replication in Treatment-Experienced Patients
• CCO Slideset – New Strategies for Regaining Control of HIV Replication in Treatment-Experienced Patients

Educational Module

• Current Data and Treatment Strategies for Controlling HIV Replication in Multiclass-Experienced Patients

Managing Metabolic Issues and Cardiovascular Risk in HIV-Infected Patients

Modules

• Update on Metabolic Complications in HIV

Interactive Case Challenges

• Antiretroviral management of a treatment-naive, HIV-infected patient with significant cardiovascular risk factors
• Individualizing antiretroviral therapy in treated HIV-infected patients with dyslipidemia
• Management of an HIV-Positive Patient With Insulin Resistance While On Antiretroviral Therapy

Corresponding PowerPoint Slides for the Module

• Update on Metabolic Complications and Cardiovascular Disease in HIV-Infected Adults

Primary Care and Prevention

Modules

• HIV Prevention in the Treatment Setting
• Evaluation and Management of the Newly Diagnosed HIV-Positive Patient

Downloadable Checklists for First Encounter With Newly Diagnosed HIV-Positive Patient

• Physical Examination Checklist
• Baseline Laboratory Test Checklist, Part 1: HIV-Related and Hematologic Tests
• Baseline Laboratory Test Checklist, Part 2: Chemistry and Metabolic Tests
• Baseline Laboratory Test Checklist, Part 3: Serologic Tests
• Baseline Laboratory Test Checklist, Part 4: Other Infections and Cancers
• Download All Checklists in one document

New and Investigational Anti-HIV Agents: Switching Strategies and Durability

Modules

• Novel Antiretroviral Agents
• Fusion Inhibition: Optimal Use of Enfuvirtide
• Investigational Protease Inhibitor: Role of Tipranavir
• Treatment Strategies for Optimizing the Benefits of New Agents

Interactive Case Challenges

• Management of a Highly Treatment-Experienced HIV-Infected Patient With Multiclass Resistance
• Management of a Young HIV-infected Woman Failing First-line Antiretroviral Therapy

CCO Slidesets

• Fusion Inhibition: Optimal Use of Enfuvirtide
• Novel Antiretroviral Agents
• Treatment Strategies for Optimizing the Benefits of New Agents
• Investigational Protease Inhibitor: Role of Tipranavir

The Economics of HIV in the HAART Era

Modules

• The Economics of HIV in the HAART Era

The New Anatomy of Effective Antiretroviral Therapy

Modules

• Backbone: Safety and Efficacy of Novel NRTI Combinations
• Metabolism: Novel Data on Antiretroviral Drug-Drug Interactions
• Brain: Reasons and Strategies for Switching Antiretrovirals in Patients With Virologic Suppression
• Heart: Ensuring Access and Effective Use of Antiretrovirals in Resource-Limited Settings

CCO Slidesets

• Metabolism: Novel Data on Antiretroviral Drug-Drug Interactions
• Brain: Reasons and Strategies for Switching Antiretrovirals in Patients With Virologic Suppression
• Backbone: Safety and Efficacy of Novel NRTI Combinations
• Heart: Ensuring Access and Effective Use of Antiretrovirals in Resource-Limited Settings

New Standards and Strategies in Antiretroviral Therapy

Modules

• Advances in Once-Daily Antiretroviral Therapy
• Antiretroviral Therapy and Metabolic Complications: An Update
• Strategic Sequencing and Response to Early Treatment Failure
• Managing Treatment-Experienced Patients: New Strategies for Success

Resistance Testing in HIV

Modules

• The Role of Resistance Testing in Treatment-Naive HIV-Infected Individuals
• Genotyping vs Phenotyping: Which Test When?
• Nucleoside-Associated Mutations in HIV-1 Reverse Transcriptase: Mechanisms, Mutational Patterns, and Management
• Implications of Protease Inhibitor Resistance Patterns for Sequential Use of Protease Inhibitors

CCO Slidesets

• May - The Role of Resistance Testing in Treatment-Naive HIV-Infected Individuals
• June - Genotypic vs Phenotypic Resistance Testing: Which Test When?
• July - Nucleoside Analogue Mutations (NAMs): Mechanisms, Mutational Patterns, and Management
• August - Implications of Protease Inhibitor Resistance Patterns for Sequential Use of Protease Inhibitors

HIV Lessons Learned

Modules

• Changing Approaches To Interpreting Phenotypic Resistance Testing In HIV-Infected Patients
• HIV Lessons Learned: Lipodystrophy: One Syndrome With Phenotypic Variations, or Multiple Unrelated Syndromes?
• HIV Lessons Learned: Use of HIV Drug Resistance Testing in Treatment Failure
• HIV Lessons Learned: The Perils Of Extrapolation: Combination NRTI Use
• HIV Lessons Learned: Structured Treatment Interruptions: Hypothesis-Driven Research or Treatment Fad?
• HIV Lessons Learned: Induction/Maintenance Strategies: Simpler Is Not Always Better

New Agents and Treatment Strategies for Treatment-Experienced HIV Patients

Modules

• New Antiretroviral Agents: Are They Worth the Wait?
• New Data: Long-Term Studies in Treatment-Experienced Patients
• New Strategies: Optimizing Antiretroviral Therapy for Treatment-Experienced Patients
• New Paradigms in the Management of Treatment-Experienced Patients

Interactive Case Challenges

• Management of a Modestly Treatment-Experienced Patient After Prolonged Treatment Interruption
• Management of a Multiclass-Experienced HIV-Infected Patient with Virologic Failure